Search

By Industry Solutions (2)
By Phase (1)
By Molecule Type (1)
By Therapeutic Area (3)
Covance Events (9)
Geography (3)
Keywords (10)

Filters

Showing results 1201 - 1216 of 91813 for .

Showing results 1201 - 1216 of 91813 for .

Sports Nutrition
Experienced. Trusted. Responsive. Club and team nutritionists worldwide rely on the sports nutrition formulation capabilities of Covance food scientists and project managers. As our partner, you'll experience the benefits of our unparalleled knowledge, industry-wide network of consumer packaged food experts and a broad range of integrated solutions to span your product's lifecycle.
Library of Claims Databases & Survey Databases
Learn more about the library of claims and survey databases.
Stability and Shelf Life Solutions
Stability and Shelf Life Solutions
Focus on Your Molecule's Future
Find out why stakeholder research is a critical foundation in a successful market access strategy.
Technical Feasibility Assessments
Unlocking Innovation. Identifying and Solving Technical Hurdles. You need a team of product and process developers plus food safety experts to collaborate on and conduct holistic technical feasibility studies. Address technical roadblocks that delay new concept development, and avoid being derailed by unforeseen technical hurdles at the end of your product development cycle. Move this assessment to your early concept evaluation and screening process-or even before development.
SEND Sell Sheet
SEND Sell Sheet
Unique Testing Solutions for Virology Clinical Trials
Drive innovation in your anti-viral therapies with our proprietary assay technologies and diverse global solutions.
Xcellerate® Informatics
Find out how stronger insights and greater oversight through the combined capabilities of the Xcellerate Informatics Platform can optimize your clinical trial outcomes.
Xcellerate® Insights: Track Trial Performance. Anytime, Anywhere.
Your clinical trial is moving quickly toward its next milestone, and you want to be prepared to make informed decisions on how best to proceed. Ensure that every member of your team is up to date with the latest information through the collaborative workspace of Xcellerate® Insights.
Xcellerate® Monitoring Software as a Service (SaaS)
Read about the industry's first global, centralized monitoring SaaS solution, Xcellerate® Monitoring.
Xcellerate® Study Start Up
Study startup represents one of the most critical yet challenging stages in your clinical journey. Set your trial in motion by starting on the right foot with Xcellerate® Study Start Up.
Avastin® (Bevacizumab) Biosimilar CmC Analytical Solutions
The successful development of a biosimilar presents unique challenges compared to that of an innovator biologic. In particular, one must prove the biosimilar candidate's structural and functional differences do not have a meaningful impact on the clinical safety and efficacy profile already established for the innovator. Comprehensive and rigorous analytical testing to assess biosimilarity is thus the foundation upon which the successful development of a biosimilar begins.
Monoclonal Antibodies CMC Analytical Solutions
Reaching development milestones faster and effectively managing your program from discovery to post-launch requires specialized expertise and end-to-end solutions. Whether your ultimate objective is regulatory filing, commercial release or managing the product lifecycle, we'll help you to make smarter decisions faster.
The EOGRTS (Extended One-Generation Reproductive Toxicity Study) - A Practical Approach
The approved guideline (OECD 443, adopted 28 July 2011) for the extended one-generation reproductive toxicology study (EOGRTS) has provided a standard regulatory outline that allows the chemical industry to better understand the mechanisms of the toxicology observed.
Humira® (Adalimumab) Biosimilar CmC Analytical Solutions
The successful development of a biosimilar presents unique challenges compared to that of an innovator biologic. In particular, one must prove the biosimilar candidate's structural and functional differences do not have a meaningful impact on the clinical safety and efficacy profile already established for the innovator. Comprehensive and rigorous analytical testing to assess biosimilarity is thus the foundation upon which the successful development of a biosimilar begins.